论文部分内容阅读
目的观察布地奈德福英特罗(信必可都保)和沙美特罗替卡粉吸入剂(舒利迭)治疗咳嗽变异性哮喘的疗效。方法选取咳嗽变异性哮喘患者40例作为研究对象,随机分为观察组和对照组,每组20例。观察组采用吸入布地奈德福模特罗治疗,对照组采用沙美特罗替卡松治疗。观察比较2组治疗前、治疗1周及治疗2周时肺功能情况。结果 2组临床症状均得到改善,2组第一秒用力呼气量(FEV1)均有提高,观察组治疗早期呼气峰流速(PEF)提高较对照组显著(P<0.05)。2组均未发生不良反应。结论信必可都保和舒利迭对咳嗽变异性哮喘患者肺功能改善均有效果,但信必可都保起效更快,值得临床推广应用。
Objective To observe the curative effect of budesonide felodiprolein (SINK) and salmeterriptamine powder inhaler (seretide) on cough variant asthma. Methods Forty patients with cough variant asthma were randomly divided into observation group and control group, with 20 cases in each group. The observation group was treated with inhaled budesonide model and the control group was treated with salmeterol and fluticasone. The pulmonary function of two groups before treatment, one week after treatment and two weeks after treatment were observed and compared. Results The clinical symptoms were improved in both groups. FEV 1 in both groups increased, and the early peak expiratory flow (PEF) in observation group was significantly higher than that in control group (P <0.05). No adverse reactions occurred in both groups. Conclusions Both of them are effective in improving lung function in patients with cough variant asthma. However, they are all effective in improving the lung function of patients with cough variant asthma, but they are worthy of clinical application.